Gene and CAR T-cell therapies are receiving much attention – both for the hope they offer patients and their million-dollar+ cost. Understandably, many employers and their advisors are focused on how to pay for these therapies. However, the initial questions employee benefits leaders should ask are: Do these therapies work? And should I pay for them?

Webinar Agenda:

• Overview of Gene and CAR T-cell therapies and the conditions they treat.
• Best practices on reviewing the clinical literature to determine if these therapies offer a patient-specific cure, improvement over existing treatment, or neither.
• How to evaluate your financial risk.
• Deep dive into the new Hemophilia gene therapies that cost more than $3M each.